Gilead Sciences Inc. (NASDAQ:GILD) said Monday it signed royalty-free voluntary licensing agreements with three generic drugmakers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis for Ebola Bundibugyo virus disease.
The agreements span 127 primarily low- and lower-middle-income nations, matching the geographic reach of Gilead’s existing COVID-19 licenses for remdesivir.
This territory includes every African country reporting cases during the current Ebola BVD outbreak.
Gilead partnered with Dr. Reddy’s Laboratories (NYSE:RDY), Eva Pharma and Ferozsons Laboratories to advance manufacturing readiness, technology transfer and supply planning.
Technology transfer discussions are already underway, and Gilead is negotiating agreements with additional manufacturers.
If clinical data and regulatory authorizations support obeldesivir, these drugmakers will manufacture and supply the therapy across the licensed region.
Regulators have not yet approved obeldesivir for filovirus disease prevention or any other indication in any country.
ALIMA and its partners coordinate the ongoing Phase 3 EBO-PEP randomized, placebo-controlled field trial to evaluate obeldesivir in people facing high Ebola BVD exposure risk.
Researchers previously studied the drug in COVID-19 and RSV trials, and it showed preclinical activity across multiple filoviruses.
Gilead is also updating its existing voluntary licenses for remdesivir to cover filovirus disease.
The expansion supports potential future access if the World Health Organization-sponsored PARTNERS trial supports remdesivir as an Ebola BVD treatment and regulators grant approval.
To bolster immediate outbreak preparedness, Gilead recently donated more than 2,000 vials of remdesivir to Kenya for investigational treatment and post-exposure use.
Across the Democratic Republic of the Congo, Uganda and Kenya, Gilead’s compassionate use donations exceed 38,000 vials.
Remdesivir, a nucleotide analog prodrug, demonstrates broad-spectrum activity in laboratory and animal studies against Marburg, Ebola, SARS, MERS and SARS-CoV-2.
Roughly 50 countries approve remdesivir for COVID-19, reaching more than 14.5 million patients globally, including over 8.1 million people in low- and middle-income nations through voluntary licensing.
GILD Price Action: Gilead Sciences shares were up 0.20% at $167.92 at the time of publication Tuesday, according to Benzinga Pro data.
Photo: Sundry Photography / Shutterstock